echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Your eyes reveal the risk of Alzheimer's disease

    Your eyes reveal the risk of Alzheimer's disease

    • Last Update: 2021-09-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Amyloid plaques are protein deposits that accumulate between brain cells, which hinder function and ultimately lead to neuronal death


    However, amyloid deposition not only occurs in the brain, but may also occur in the eyes of the "window of the mind"


    In a small cross-sectional study, a research team led by the University of California San Diego School of Medicine compared the A4 study and another study (longitudinal assessment of amyloid and neurodegeneration risk) in patients’ retina and brain amyloid levels , To assess the individual’s risk of neurodegeneration


    Researchers have observed that the presence of retinal plaques in the eyes is associated with brain amyloid found in brain scans, indicating that it is expected to become a biomarker of AD


    The results of these studies were published in the journal Alzheimer's & Dementia on August 17


    Robert Rissman, professor of neuroscience at the University of California, San Diego School of Medicine, said: "This is a small initial data set involving eight patients


    "However, these results are encouraging because they indicate that it is possible in the future to determine the onset, spread, and morphology of AD through retinal imaging, rather than the more difficult and expensive brain scans


    Rissman said that the next step will be to conduct a larger study to more comprehensively record and determine the relationship between retinal amyloid and brain amyloid, including cross-sectional and longitudinal


    ###

    Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial

    First published: 17 August 2021 https://doi.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.